Reported 18 days ago
Merck is facing significant challenges with its key growth products, such as the cancer drug Keytruda and the HPV vaccine Gardasil, raising concerns about the company's ability to achieve a 38% compound annual growth rate needed to grow a $10,000 investment to $50,000 by 2030. Despite some recent approvals that could boost its prospects, analysts suggest that Merck may not outperform the market in the near term, making it a less attractive option for aggressive investors.
Source: YAHOO